Resources
Search all resources on this page or select a tab to see publications, videos, audio, collections of related resources and more.
![Cover image for Electronic Prescriptions Data Usage Policy]()
Electronic Prescriptions Data Usage Policy
This policy describes how personal information and related data contained in electronic prescriptions is collected, used and disclosed.
![Cover image for Electronic Prescriptions Privacy Policy]()
Electronic Prescriptions Privacy Policy
This policy outlines the privacy responsibilities of non-government organisations involved in the electronic prescribing process.
![Cover image for Electronic Prescriptions Security and Access Policy]()
Electronic Prescriptions Security and Access Policy
The Electronic Prescriptions Security and Access Policy describes how health care provider organisations must manage the security and integrity of their software, to make sure they dispense electronic prescriptions securely.
![LSDPEP 8th meeting agenda – 19 February 2021 cover image]()
LSDPEP 8th meeting agenda – 19 February 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.
![Cover image of LSDPEP 7th meeting agenda – 22 and 23 October 2020]()
LSDPEP 7th meeting agenda – 22 and 23 October 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.
![Cover image of LSDPEP 6th meeting agenda – 25 and 26 June 2020]()
LSDPEP 6th meeting agenda – 25 and 26 June 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.
![Cover image of LSDPEP 5th meeting agenda – 16 and 17 April 2020]()
LSDPEP 5th meeting agenda – 16 and 17 April 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.
![Cover image of eliglustat (Cerdelga®) outcome statement]()
Life Saving Drugs Program – Eliglustat (Cerdelga®) outcome statement
This document states the outcome of Sanofi-Aventis Australia's application to include eliglustat on the Life Saving Drugs Program.
![Cover image of cerliponase alfa outcome statement]()
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.
![Cover image of asfotase alfa outcome statement]()
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
![Cover image of HT1 initial application form]()
Life Saving Drugs Program – Hereditary tyrosinaemia (type 1) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Hereditary tyrosinaemia type 1![Cover image of PNH initial application form]()
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for paroxysmal nocturnal haemoglobinuria for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria![Cover image of Fabry disease initial application form]()
Life Saving Drugs Program – Fabry disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Fabry disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Fabry disease![Cover image of Pompe disease initial application form]()
Life Saving Drugs Program – Pompe disease – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Pompe disease![Cover image of MPS I initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)![Cover image of MPS II initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)![Cover image of MPS IVA initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type IVA (MPS IVA) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)![Cover image of MPS VI initial application form]()
Life Saving Drugs Program – Mucopolysaccharidosis type VI (MPS VI) – Initial application
Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.
Part of a collection: Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)![Cover image of meningococcal vaccination certificate]()
Life Saving Drugs Program – Paroxysmal nocturnal haemoglobinuria – Meningococcal vaccination certificate
Treating physicians use this document to certify their patient's meningococcal vaccination status when applying or reapplying for eculizumab through the Life Saving Drugs Program.
Part of a collection: Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type I (MPS I)
A collection of resources for health professionals to help people with mucopolysaccharidosis type I (MPS I) access laronidase (Aldurazyme®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Paroxysmal nocturnal haemoglobinuria
A collection of resources for health professionals to help people with paroxysmal nocturnal haemoglobinuria access eculizumab (Soliris®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type II (MPS II)
A collection of resources for health professionals to help people with mucopolysaccharidosis type II (MPS II) access idursulfase (Elaprase®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type IVA (MPS IVA)
A collection of resources for health professionals to help people with mucopolysaccharidosis type IVA (MPS IVA) access elosulfase alfa (Vimizim®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Mucopolysaccharidosis type VI (MPS VI)
A collection of resources for health professionals to help people with mucopolysaccharidosis type VI (MPS VI) access galsulfase (Naglazyme®) under the Life Saving Drugs Program.
![Default image]( "Default image")
Life Saving Drugs Program resources – Pompe disease
A collection of resources for health professionals to help people with Pompe disease access alglucosidase alfa (Myozyme®) under the Life Saving Drugs Program.
